000 | 02011cam a2200349 a 4500 | ||
---|---|---|---|
003 | EG-GiCUC | ||
005 | 20250223032207.0 | ||
008 | 190216s2018 ua dh f m 000 0 eng d | ||
040 |
_aEG-GiCUC _beng _cEG-GiCUC |
||
041 | 0 | _aeng | |
049 | _aDeposite | ||
097 | _aPh.D | ||
099 | _aCai01.11.07.Ph.D.2018.Fa.S | ||
100 | 0 | _aFatma Abdelwahab Abdelmaksoud | |
245 | 1 | 0 |
_aStudy of long non coding RNA hotair expression in acute myeloid leukemia / _cFatma Abdelwahab Abdelmaksoud ; Supervised Mona Salah Eldin Hamdy , Hamdy Mohamed Zawam , Nohair Soliman Mohamed |
246 | 1 | 5 | _aدراسه الحمض النووى الريبوزى الطويل والغير حامل لشفرة وراثيه (هوت اير) فى سرطان النخاع الميلودى الحاد |
260 |
_aCairo : _bFatma Abdelwahab Abdelmaksoud , _c2018 |
||
300 |
_a204 P. : _bcharts , facsimiles ; _c25cm |
||
502 | _aThesis (Ph.D.) - Cairo University - Faculty of Medicine - Department of Clinical and Chemical Pathology | ||
520 | _aAML treatment has improved over the last few decades, with improvements in risk assessment, post-remission chemotherpy, and hematopoietic stem-cell transplantation. cytogenetic and molecular markers are now considered as core standard for risk stratification and selecting therapy. long non-cording RNAs (LncRNA) are now considered as biomarkers for different due to their eqigenetic regulator effects. In this study, the expression of HOTAIR LncRNA in AML cases was compared to controls and correlation to patients Chemicopathological factors | ||
530 | _aIssued also as CD | ||
653 | 4 | _aAcute Myeloid Leukemia (AML) | |
653 | 4 | _aHOTAIR LncRNA | |
653 | 4 | _aRNAs | |
700 | 0 |
_aHamdy Mohamed Zawam , _eSupervisor |
|
700 | 0 |
_aMona Salah Eldin Hamdy , _eSupervisor |
|
700 | 0 |
_aNohair Soliman Mohamed , _eSupervisor |
|
856 | _uhttp://172.23.153.220/th.pdf | ||
905 |
_aNazla _eRevisor |
||
905 |
_aShimaa _eCataloger |
||
942 |
_2ddc _cTH |
||
999 |
_c70199 _d70199 |